APEIRON Biologics AG

Apeiron is a private biotech company in Vienna, engaged in immuno-oncology. Ist lead project APN311, a antitumor antibody against GD2, expressed on neuroblastoma and other malignancies, recently was submitted for marketing authorization in the EU for neuroblastoma therapy. Two innovative projects are devoted to checkpoint blockade to empower the immune system against cancer: APN401 is a cellular therapy in Phase I, APN411 a low molecular drug approach pursued together with Sanofi and Evotec.

  • Mitarbeiterzahl

    26
  • Ausrichtungen
    • Therapie-Entwickler
  • Gegründet

    2003
  • Aktualisiert am

    30.05.2018